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Dependency on tumor oxygenation is one of the major features of radiation therapy and this has led many radiation biologists
and oncologists to focus on tumor hypoxia. e �rst approach to overcome tumor hypoxia was to improve tumor oxygenation
by increasing oxygen delivery and a subsequent approach was the use of radiosensitizers in combination with radiation therapy.
Clinical use of some of these approaches was promising, but they are not widely used due to several limitations. Hypoxia-inducible
factor 1 (HIF-1) is a transcription factor that is activated by hypoxia and induces the expression of various genes related to the
adaptation of cellular metabolism to hypoxia, invasion and metastasis of cancer cells and angiogenesis, and so forth. HIF-1 is a
potent target to enhance the therapeutic effects of radiation therapy. Another approach is antiangiogenic therapy.e combination
with radiation therapy is promising, but several factors including surrogate markers, timing and duration, and so forth have to be
optimized before introducing it into clinics. In this review, we examined how the tumor microenvironment in�uences the effects
of radiation and how we can enhance the antitumor effects of radiation therapy by modifying the tumor microenvironment.
1. Introduction
How radiation therapy shows antitumor effects is important
in understanding the relationship between themicroenviron-
ment and radiation therapy. Cytotoxicity due to radiation
is primarily attributed to damage to genomic DNA which
contains all the genetic instructions for the development and
functions of all living organisms. Radiation can affect atoms
and/or molecules in the cells (such as water) and produce
free radicals. Because free radicals are highly reactive, they
damage genomic DNA, resulting in cell death. is is a so-
called indirect action of radiation. On the other hand, when
radiation is directly absorbed by DNA, the atoms in the DNA
are ionized and damaged. is is a so-called direct action
of radiation. Whether radiation acts directly or indirectly
depends on the linear energy transfer (LET) of radiation,
which is the energy transferred per unit length of track. e
direct action is dominant with heavy charged ion beams
whose LETs are high. Meanwhile, about two thirds of the
biological damage due to X-, 𝛾𝛾-rays, and proton beams is
caused by indirect action because their LETs are low. us,
except for heavy charged ion beams, damage to genomic
DNA is mainly caused by the indirect effects of free radicals
and becomes permanent in the presence of oxygen.erefore,
tumor hypoxia and angiogenesis, which in�uence tumor
hypoxia, have been extensively studied in order to improve
the antitumor effects of radiation therapy.
2. TumorMicroenvironments That Affect
the Therapeutic Effect of Radiation Therapy
e microenvironment of malignant solid tumors is totally
different from that of normal tissues, being characterized by
marked diversities in pH, the distribution of nutrients, and
oxygen concentrations, and so forth [1–4]. To understand
this heterogeneity is important in cancer radiation therapy
because it in�uences the effect of ionizing radiation through
various mechanisms as described in the following. Since
the tumor microenvironment is a unique feature, it can
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be a potent target for cancer therapy. However, the tumor
microenvironment is not stable and is changed by treatments,
so we have to consider effects on the microenvironment
due to both radiation therapy and tumor microenvironment-
targeting treatments that can in�uence the therapeutic out-
come.
2.1. Tumor Hypoxia
2.1.1. Tumor Hypoxia and Radioresistance. In 1955, om-
linson and Gray reported a milestone study showing that
partial oxygen pressure (pO2) is highly diverse in amalignant
solid tumors; some regions are well oxygenated and others
are exposed to low oxygen conditions, that is, hypoxia [3].
It has been reported that the hypoxic fraction (pO2 < or =
2.5mm Hg) is approximately 25% in malignant tumors such
as uterine cervix cancers, head and neck cancers, and breast
cancers [5]. In contrast, there is no region where pO2 values
are lower than 12.5mmHg in normal tissues such as normal
breast tissues [6]. Tumor hypoxia has drawn considerable
attention in radiation oncology because it has been strongly
associated with radioresistance of malignant tumors, tumor
recurrence aer radiation therapy, and poor prognosis of
cancer patients aer radiation therapy, and so forth [7–9].
2.1.2. Chronic and Acute Hypoxia. Tumor hypoxia can be
grouped into two distinct categories; chronic hypoxia and
acute hypoxia, according to the causative factors and the
duration for which tumor cells are exposed to hypoxic
conditions [7, 10].
Cancer cells generally have unique characteristics, such
as accelerated proliferative signaling, evasion of growth
suppressors, replicative immortality, and deregulated cellular
energetics [11]. Also, vasculatures in malignant tumors are
different from those in normal tissues and are functionally
and structurally defective in most malignant solid tumors
[12]. ese peculiarities are known to cause an imbalance
between oxygen supply and oxygen consumption in malig-
nant solid tumors and to be major causative factors in
severely compromised oxygenation in some parts of malig-
nant tumors [1–4]. Proliferation of tumor cells is dependent
on the supply of oxygen and nutrients; therefore, a tumor
blood vessel is surrounded by actively proliferating cancer
cells. is is generally called a normoxic region [2, 3, 13].
On the other hand, cancer cells inevitably die in areas
approximately 100 𝜇𝜇m from tumor blood vessels, known as
necrotic regions [2, 3, 13]. Between these two distinct regions,
there are chronically hypoxic regions in which cancer cells
obtainminimal levels of oxygenmolecules from tumor blood
vessels, adequate for their survival but insufficient for their
active proliferation (Figure 1) [2, 3, 13].us,mostmalignant
tumors individually grow as a conglomerate of so-called
microtumor cords [2, 3, 13].
Acute hypoxia was �rst recognized by Brown et al. in
1979 [10]. ey reported that structurally and functionally
anomalous tumor vasculatures cause the transient opening
and closing of blood vessels. is leads to changes in the
blood �ow rate and �uctuations in perfusion and ultimately




















functional blood vessels by an imbalance between
Acute hypoxia is caused by the transient opening and
closing of  tumor blood vessels and resultant changes
in blood flow rate and fluctuations in perfusion
O2 supply andO2 consumption in a solid tumor
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F 1: Chronic and acute hypoxia. See main text for details
(Modi�ed �gure from [14]).
of tumor blood vessels (Figure 1). It is said that at least 20%
of cancer cells experience acute hypoxia in malignant solid
tumors. Both acute/intermittent/cycling and chronic hypoxia
have receivedmuch attention because of their relevance to the
malignancy and radioresistance of cancer cells [15, 16].
2.1.3. Mechanism behind Radioresistance of Cancer Cells
under Hypoxia. �xtensive research in the �eld of radiation
biology and radiation oncology has revealed that cancer cells
become approximately 2-3 times more radioresistant under
hypoxic conditions than under normoxic conditions. is
phenomenon is known as the oxygen effect. e mechanism
behind the oxygen effect has not yet been fully elucidated.
However, it is widely believed that oxygen acts at the level of
the generation of free radicals [7, 13, 17]. Ionizing radiation
literally induces ionization of target genomic DNA or intra-
cellular molecules such as water, and produces highly reac-
tive radicals. Under oxygen-available conditions, molecular
oxygen oxidizes the DNA radicals, leading to the formation
of irreparable DNA damage. On the other hand, under
hypoxic conditions, oxygen-depletion is known to primarily
disturb the production of reactive and cytotoxic species due
to ionizing radiation. Moreover, DNA radicals, which are
barely produced under hypoxia, can be chemically reduced by
sulydryl (SH) group-containing materials, resulting in the
prevention of DNA damage. us, irreparable DNA double
strand breaks (DSBs) are signi�cantly less serious in the
absence of oxygen, leading to hypoxia-related radioresistance
of cells.
2.2. HIF-1. In addition to radiochemical mechanisms, hyp-
oxia is also known to increase tumor radioresistance at the
tissue level through some biological mechanisms. Accumu-
lated evidence revealed the important role of a transcription
factor, hypoxia-inducible factor 1 (HIF-1) [1, 14, 18–20].
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F 2: Regulation of HIF-1 activity. See main text for details.
2.2.1. Regulation of HIF-1 Activity. HIF-1 is a heterodimeric
factor composed of an 𝛼𝛼-subunit (HIF-1𝛼𝛼) and a 𝛽𝛽-subunit
(HIF-1𝛽𝛽). Its hypoxia-dependent activity is regulated at
multiple levels, such as translational initiation, degrada-
tion/stabilization, and upregulation of transactivation activ-
ity of HIF-1𝛼𝛼 (Figure 2). In the presence of oxygen, HIF-
1𝛼𝛼 is hydroxylated by prolyl hydroxylases (PHDs) and sub-
sequently ubiquitinated by a pVHL-containing E3 ubiquitin
ligase, resulting in rapid degradation [21–24]. On the other
hand, HIF-1𝛼𝛼 is stabilized under hypoxic conditions because
of a decrease in PHD activity and interacts with HIF-1𝛽𝛽.
e resultant HIF-1 binds to its cognate transcriptional
enhancer sequence, the hypoxia-responsive element (HRE),
and induces the expression of various genes related to the
adaptation of cellularmetabolism to hypoxia (the switch from
oxidative to anoxic respiration) [25], escaping from hypoxia
(invasion andmetastasis of cancer cells) [26, 27], and reduces
hypoxia (angiogenesis) [28, 29], and so forth.
In addition to the PHDs-VHL-mediated mechanism,
other mechanisms have been reported to function in the reg-
ulation of HIF-1 activity (Figure 2). For example, stability of
HIF-1𝛼𝛼 is also regulated in a receptor of activated protein
kinase C (RACK1)-dependent manner [30]. Interaction with
RACK1 leads to the oxygen-independent degradation of
HIF-1𝛼𝛼 because RACK1 competitively inhibits the interac-
tion of HIF-1𝛼𝛼 to heat shock protein 90 (HSP90) which stabi-
lizes the HIF-1𝛼𝛼 protein. Also, it was recently elucidated that
HIF-1𝛼𝛼 protein synthesis depends on a phosphatidylinositol
3-kinase (PI3K-) Akt-mammalian target of the rapamycin
(mTOR) signaling transduction pathway because of the
existence of a polypyrimidine tract in the 5�-untranslated
region of HIF-1𝛼𝛼 mRNA [31, 32]. Furthermore, the post-
translational modi�cation of HIF-1𝛼𝛼 also plays a critical role
in stimulating the transactivational activity of HIF-1 [33].
Under normoxic conditions, factor inhibiting HIF-1 (FIH-
1) becomes active and hydroxylates an asparagine residue
(N803) of HIF-1𝛼𝛼 [21, 33]. e hydroxylation blocks the
recruitment of co-factors p300 and CBP, resulting in the
suppression of HIF-1,s transactivational activity. Phosphory-
lation of HIF-1𝛼𝛼 by mitogen-activated protein kinase (MAP
kinase) and ERK signaling pathways is also known to play
an important role in the upregulation of its transactivation
activity.
2.2.2. Radioresistance of Tumor Cells via a HIF-1-Mediated
Biological Mechanism. An interesting model for the role of
HIF-1 in tumor radioresistance was proposed recently; (1)
radiation activates HIF-1 in a solid tumor as a result of both
the increase in oxidative stress [18, 19] and improvement
in glucose and oxygen availabilities [1, 14, 34, 35], (2)
HIF-1 induces the expression of VEGF, (3) VEGF protects
endothelial cells from the cytotoxic effects of radiation, and
(4) the radioprotected tumor blood vessels assure the supply
of oxygen and nutrients to tumor cells and promote tumor
growth [18, 35–37]. e feasibility of this model has been
con�rmed by the following data. Optical imaging using an
HIF-1-dependent reporter gene revealed that intratumor
HIF-1 activity is dramatically induced by radiation therapy
[18, 34, 35, 38, 39]. A hypoxia-conditioned medium, which
contained a high level of VEGF, signi�cantly reduced the
incidence of radiation-induced apoptosis of human umbilical
vein endothelial cells in vitro [35–37]. An HIF-1 inhibitor,
YC-1, or a neutralizing antibody against VEGF dramatically
induced apoptosis of endothelial cells and reduced microves-
sel density aer radiation therapy, resulting in a radiosensi-
tizing effect in a tumor growth delay assay [18, 35, 40].
In addition to such indirect mechanisms of action, our
group recently revealed a direct function of HIF-1 in tumor
recurrence aer radiation therapy [41]. �e �rst developed a
sophisticated strategy to track the post-irradiation fate of the
cells which were present in perinecrotic regions at the time
of radiation. e cell tracking experiment revealed that the
perinecrotic cells predominantly survived radiation therapy
and directly caused recurrent tumors. Although the per-
inecrotic cells did not originally express HIF-1, they acquired
HIF-1 activity aer surviving radiation. Interestingly, the
activation of HIF-1 triggered the migration of the radio-
surviving cells towards functional tumor blood vessels and
eventually caused tumor recurrence.
2.3. Tumor Angiogenesis. For solid tumors, angiogenesis is
necessary to grow over a diameter of 2mm to obtain oxygen
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T 1: Antiangiogenic agents with radiosensitizing potentials.
Category Representative strategies/protein/drugs References
Endogenous angiogenesis inhibitor Angiostatin, [45–47]
Endostatin [48–50]
Anti-VEGF antibody Bevacizumab [36, 40, 52–54]
Anti-VEGFR antibody DC101 [43, 55]
Anti-VEGFR tyrosine kinase inhibitor and multitarget
tyrosine kinase inhibitor
Vatalanib (PTK787), [56, 57]
Vandetanib (ZD6474), [58, 59]
Cediranib (AZD2171) [60, 61]
Semaxanib (SU5416), [62, 63]
SU6668 [64]
SU11657 [44]
Sunitinib (SU11248) [65, 66]
Others TNP-470 [51, 67, 68]
alidomide [69]
and nutrients. e angiogenic switch is a critical step in the
process of tumor growth; an initial avascular tumor nodule
becomes a rapidly growing, highly vascularized tumor. e
concept that blockage of angiogenesis could be a target in
cancer therapy was proposed in 1971 by Judah Folkman
[42]. Antiangiogenic therapy has an advantage that targeting
endothelial cells without geneticmutations should lead to less
resistance to the antiangiogenic treatment. However, the use
of antiangiogenic agents has a limitation in that they cannot
eradicate tumors as monotherapy and need to be combined
with cytotoxic therapy. e combination of antiangiogenic
therapy and radiation therapy showed synergic effects in
several preclinical models despite the prediction that antian-
giogenic therapy would increase tumor hypoxia. In clinics,
the role of the combination of antiangiogenic therapy and
radiation therapy is still under investigation.
2.3.1. Combination of Radiation erapy and Antiangiogenic
erapy. e synergistic effects of the combination of radia-
tion therapy and antiangiogenic agents have been reported
in several preclinical studies (Table 1). Gorski et al. [36]
showed that an anti-VEGF antibody alone did not suppress
the growth of U87 glioblastomas, but when it was combined
with radiation, it showed a signi�cant improvement in
terms of antitumor effects. Kozin et al. [43] observed that
DC101, an anti-VEGFR2 antibody, enhanced the effects of
radiation therapy in 54A non-small cell lung cancer and U87.
Several tyrosine kinase inhibitors were developed to block the
VEGF receptor and other receptors that are proangiogenic.
For example, Huber et al. [44] reported that SU11657,
which inhibits VEGF, PDGF and C-kit, also enhanced the
effects of radiation with chemotherapy on A431 tumors,
and that triple inhibition was more effective than blockade
of each single target. Synergistic antitumor effects in the
combination with radiation therapy were also reported for
angiostatin [45–47] and endostatin [48–50]. In contrast,
Murata et al. [51] observed that the concurrent treatment
of mouse breast carcinoma xenogras with TNP-470 and
fractionated radiation therapy resulted in reduced tumor
control and tumor oxygenation decreased. Although many
preclinical studies showed enhanced antitumor effects in the
combination of antiangiogenic agents and radiation therapy,
this study indicated the possibility that a schedule of both
radiation therapy and antiangiogenic therapy could in�uence
the therapeutic outcome.
2.3.2. Vascular Normalization. Tumor angiogenesis is char-
acterized by tortuous, irregular, and immature vessels, and
microvessel density is inhomogeneous in the tumors. In
addition, poor coverage with pericytes leads to a marked
increase in vessel leakiness and high interstitial pressure in
the tumor. erefore, blood �ow in the tumor is insu�cient
to supply enough oxygen and nutrients even in well vascu-
larized areas in the tumor. Jain and colleagues [12] proposed
the term “vascular normalization.” At the time of angio-
genic switch, proangiogenic factors are more dominant over
antiangiogenic factors and provoke marked angiogenesis in
tumors. If proangiogenic factors and antiangiogenic factors
are balanced, disappearance of immaturemicrovessels and an
increase in pericyte coverage lead to a transient increase in
blood �ow and lower interstitial pressure. �inkler et al. [55]
demonstrated that DC 101 (a VEGFR2 inhibitor) treatment
transiently increased tumor oxygenation and synergistic
effects were observed when radiation was combined during
this period. is concept can also explain why the combi-
nation of antiangiogenic agents and cytotoxic chemotherapy
showed improved overall survival for colorectal carcinoma.
ese �ndings raised a �uestion about the best schedule
to obtain maximal effects of combination of radiation and
antiangiogenic therapy.
2.3.3. Sequence of Radiation erapy and Antiangiogenic
erapy. If antiangiogenic agents can improve the tumor
oxygenation by vascular normalization, the timing of radi-
ation should be aer antiangiogenic therapy, and preclinical
studies indicated the possibility that its long-term use may
lead to an increase in tumor hypoxia. Dings et al. [52] studied
the combination of bevacizumab, anginex, an antiangiogenic
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peptide, and radiation therapy. ey found signi�cantly
increased tumor oxygenation in the four days aer the
start of treatment. When radiation was combined during
this period, tumor growth delay was extended. Although
our group could not show a transient increase in tumor
hypoxia with bevacizumab treatment, we could show an
increase in tumor hypoxia 72 hours aer administration
by HIF-1 imaging [40]. If the radiation was combined 24
hours aer bevacizumab treatment when HIF-1 activity was
not upregulated, enhanced antitumor effects were observed;
however, 72 hours aer bevacizumab treatment when HIF-1
activity was upregulated, antitumor effects were lower than
radiation alone. If an optimal time window for combining
radiation with antiangiogenic agents exists, its duration of
is estimated to be both tumor and host dependent. e
development of hypoxia imaging which can monitor the
changes in tumor hypoxia repeatedly is needed to determine
the optimal time window in clinics.
Not all antiangiogenic agents seem to have a vascular nor-
malization window. Williams et al. [58] found that ZD6474,
an inhibitor of VEGFR and EGFR, was most effective when
it was administered 30 minutes aer radiation therapy as
compared to concomitant administration or radiation alone.
PTK787, a VEGFR2 inhibitor, was also most effective when
administered aer fractionated irradiation, but not before or
during radiation [56].
As previously described, VEGF expression induced by
HIF-1 upregulation from radiation therapy can protect tumor
endothelial cells from apoptosis due to radiation therapy.
Both an HIF-1 inhibitor, YC-1, and a neutralizing antibody
against VEGF dramatically induced apoptosis of endothelial
cells and reduced microvessel density aer radiation therapy
and delayed tumor growth [18, 35, 40]. Endostatin also
downregulated VEGF aer radiation therapy and induced
apoptosis, reducing proliferation of endothelial cells aer
radiation therapy and signi�cantly delayed tumor growth
[49]. ese effects on endothelial cells are independent of
vascular normalization windows and can be another factor
to determine the optimal timing of the combination of
antiangiogenic therapy and radiation.
2.3.4. Endothelial Cells and Radiosensitivity. Garcia-Barros et
al. [70] showed that apoptosis of endothelial cells is mediated
by rapid generation of sphingolipid ceramide through the
hydrolysis of cell membrane sphingomyelin by the acid
sphingomyelinase (ASM) enzyme. In this study, a single
high-dose radiation (>15Gy) was used andwould be relevant
only to hypofractionated stereotactic radiotherapy such as
stereotactic body radiotherapy (SBRT) or stereotactic radio-
surgery (SRS). In this study, endothelial cell apoptosis was
directly related to tumor radiosensitivity. High local control
rates of SBRT and SRS suggest that vascular damagemay play
an important role in the response of SBRT or SRS in clinics.
3. Targeting the TumorMicroenvironment to
Improve the Effects of Radiation Therapy
In recent years it has become increasingly clear that the
e�cacy of radiation therapy is in�uenced by the tumor
microenvironment. Several classes of agents which modulate
microenvironmental factors have been developed, and some
of them have radiosensitizing potential. e two major
microenvironmental factors which in�uence the radiosensi-
tivity of tumor cells are oxygenation and angiogenesis.
3.1. Hypoxia and Radiosensitization. Hypoxia, which is com-
monly seen in malignant solid tumors, is known to be one of
the most important characteristics in the tumor microenvi-
ronment and is associated with tumor radioresistance. Since
the 1950s, many scientists have proposed a hypoxic environ-
ment tomake tumor cells more radioresistant compared with
a well-oxygenated tumor environment.
To overcome hypoxia-related radioresistance, several
methods to increase oxygen delivery, radiosensitizers for
hypoxic tumor cells, hypoxic cytotoxins, andHIF-1 inhibitors
have been developed (Table 2).
3.1.1. Increase in Oxygen Delivery. Several groups have tried
to increase the delivery of oxygen to tumor lesions through
blood �ow. Representative treatment methods are hyperbaric
oxygen therapy, carbogen with nicotinamide, blood transfu-
sion and erythropoietin.
(1) Hyperbaric Oxygen erapy. Hyperbaric oxygen (HBO)
therapy is the inhalation of 100% oxygen at elevated pressure.
It is a promising approach to cope with tumor hypoxia
by dissolving oxygen in the plasma and delivering it to
tumor sites independent of hemoglobin while increasing
the concentration of oxygen in the tumor area. e �rst
report about HBO with radiation therapy was published in
the 1960s, and since then several clinical trials have been
conducted for solid tumors such as cervical cancer, head and
neck cancer, bladder cancer and malignant glioma, but the
bene�t of this method remains controversial [71–76].
(2) Carbogen with Nicotinamide. Carbogen is a mixture of
O2 and CO2 gas. Breathing carbogen is known to reduce
diffusion-limited hypoxia. Nicotinamide, the amide deriva-
tive of vitamin B6, is a vasoactive agent which coun-
teracts acute hypoxia; administering nicotinamide reduces
perfusion-related acute hypoxia. In addition, Nicotinamide
is known to inhibit Poly ADP-ribose polymerase I which
is a critical enzyme in single stranded DNA break repair
[77], and many studies have shown that the inhibition of
poly-ADP-ribose polymerase enhances tumor radiosensitiv-
ity [78–80]. is could be also one of the rationales for
the radiosensitizing effect of the combination therapy with
carbogen and nicotinamide. Normobaric carbogen only or
carbogen plus nicotinamide therapies have been used with
radiation therapy to overcome the hypoxic radioresistance
of malignant tumors. In the 1990s, a schedule of accelerated
radiotherapywith carbogen and nicotinamide (ARCON)was
also proposed. However, the addition of carbogen breathing
to de�nitive RT did not appear to improve the likelihood of
local control for T2-4 head and neck cancers [81]. Several
clinical trials using radiotherapy with carbogen and nicoti-
namide including ARCON are now ongoing for head and
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T 2: Strategies to overcome radioresistance of hypoxic tumor cells.
Strategies Mechanisms/representative strategies or drugs
Hyperbaric oxygen therapy Direct oxygen delivery to hypoxic regions
Carbogen with nicotinamide Direct oxygen delivery to hypoxic regions/ARCON
Hemoglobin modi�cation Direct oxygen delivery to hypoxic regions
Nitroimidazole derivatives Radiosensitization by mimicking the effect of oxygen/misonidazole
Hypoxic cytotoxins Cell killing by hydroxyl radicals or an oxidizing radicals/tirapazamine
HIF-1 Inhibitors Suppression of radioresistant phenotype of hypoxic tumor cells/YC-1
Modi�ed �gure from [14].
neck cancer and bladder cancer [82, 83]. e treatment out-
come andmorbidity will determine the therapeutic bene�t of
these treatment strategies.
(3) Hemo�lobin �odi�cation ��ed �lood Cell �rans��sion
and Erythropoietin). Several preclinical and clinical stud-
ies have shown that a low hemoglobin level is related to
tumor hypoxia [84]. An increase in hemoglobin levels with
blood cell transfusions, erythropoietin, and erythropoiesis-
stimulating agents (ESAs) could be a promising method to
enhance the response to radiation therapy by increasing the
oxygen concentration of the tumor. e use of recombinant
erythropoietin or erythropoiesis-stimulating agents (ESAs)
with radiation therapy in patients with head and neck cancer
has been tested. However, radiation therapy with hemoglobin
modi�cation has no impact on clinical radiation therapy [85–
89].
3.1.2. Nitromidazole Derivatives. Nitroimidazole-based agents
such as misonidazole and nimorazole were found to mimic
the effect of oxygen and enhance the cytotoxic effect of
ionizing radiation on hypoxic malignant tumors. Several
clinical trials using these drugs have been conducted. It was
reported that the use of an effective dose of misonidazole
caused late peripheral neuropathy, while nimorazole, a less
toxic nitroimidazole-derivative, could be used at higher doses
and signi�cantly improved the radiotherapeutic effect of
supraglottic and pharyngeal cancers [90–93].
3.1.3. Hypoxic Cytotoxins. We can utilize hypoxia as a spe-
ci�c target of treatment. e most representative hypoxia-
activated prodrug is tirapazamine, and its mechanism of
action has already beenwell established [7, 94]. Tirapazamine
is subjected to one-electron reduction to a radical anion.
e radical anion can be reversibly oxidized to the parental
compound in the presence of molecular oxygen [95], but
can be further converted to a toxic hydroxyl radical or to
an oxidizing radical in the absence of oxygen [96]. Both
of the resultant radicals cause DNA DSBs, single-strand
breaks, and base damage, resulting in cell death, especially
under hypoxic conditions. Because hypoxic tumor cells are
the most radiation-resistant cells in malignant solid tumors,
tirapazamine and radiation act as complementary cytotoxins;
namely, each one kills the cells resistant to the other, thereby
enhancing the efficacy of radiation against the tumor [7].
Despite promising early results [97, 98], a phase III trial of
tirapazamine in combination with radiation therapy showed
no signi�cant difference in failure-free survival, time to
locoregional failure, or quality of life [99]. Currently, new
improved TPZ analogues with higher hypoxic potency are
being developed [100].
3.2. HIF-1 Inhibitors. Basic and clinical researches have con-
�rmed that the expression level of HIF-1𝛼𝛼, as well as absolute
low pO2, correlates with a poor prognosis and incidences
of both tumor recurrence and distant tumor metastasis aer
radiation therapy [7–9, 101–103]. Each of the multiple steps
responsible for the activation of HIF-1 has been exploited as
a therapeutic target (Figure 3).
One of themajor targets is themechanism behind the sta-
bilization of HIF-1𝛼𝛼 protein, because it is the most in�uential
step in HIF-1 activity. YC-1, which was primarily synthesized
with the aim of activating soluble guanylate cyclase and
inhibiting platelet aggregation, was reported to suppress the
expression of HIF-1 target genes through the suppression of
HIF-1𝛼𝛼 accumulation and to increase the antitumor efficacy
of radiation therapy signi�cantly [18, 35, 104, 105]. An
HSP90 inhibitor, 17-allylamino-17-demethoxygeldanamycin
(17-AAG), facilitates the RACK1-dependent ubiquitination
of HIF-1𝛼𝛼, resulting in its degradation through proteasome.
Also, antioxidant reagents such as ascorbate and N-acetyl
cystein (NAC), promote the degradation of HIF-1𝛼𝛼 protein
by reducing Fe3+ to Fe2+, which functions as a cofactor in the
PHDs-VHL-dependent degradation ofHIF-1𝛼𝛼 protein [106].
Inhibiting the dimerization of HIF-1𝛼𝛼 with HIF-1𝛽𝛽 was
also targeted because it is required for HIF-1 DNA-binding
and transcriptional activity. Lee et al. identi�ed acri�avine
as an inhibitor of the dimerization by directly binding
to HIF-1𝛼𝛼 [107]. ey reported that acri�avine treatment
inhibited intratumoral expression of angiogenic cytokines,
mobilization of angiogenic cells into peripheral blood, and
tumor vascularization, resulting in the prevention and arrest
of tumor growth [107].
Another approach is to inhibit the function of key
signaling pathways which up-regulate the expression of HIF-
1𝛼𝛼, such as the PI3K-Akt-mTOR and Ras signaling path-
ways [31, 32, 108]. An mTOR inhibitor, RAD-001, actually
reduced the level of HIF-1𝛼𝛼 protein and its downstream gene
products in a mouse model of prostate cancer with high
oncogenic Akt activity [109]. Other mTOR inhibitors, such
as rapamycin, temsirolimus (CCI-779), everolimus (RAD-
001), also showed the same effect [110]. In addition, it was
reported that doxorubicin and echinomycin suppress the
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function of HIF-1 by inhibiting HIF-1’s binding to HRE
[107, 111].
Because HIF-1 directly and indirectly functions in tumor
recurrence aer radiation therapy as described above, HIF-
1 inhibitors, as well as tirapazamine, have been con�rmed to
enhance the therapeutic effect of radiation [18, 35, 38, 41, 112,
113]. However, it has also been reported that the inhibition
of HIF-1 with unsuitable timing suppresses rather than
enhances the effect of radiation therapy because its antian-
giogenic effect increases the radioresistant hypoxic fraction in
malignant solid tumors [35]. Accumulated evidence indicates
that the suppression of the postirradiation upregulation of
HIF-1 activity is important for the best therapeutic bene�t
[18, 20, 35, 41].
3.3. Angiogenesis and Radiosensitization. Angiogenesis is
essential for tumor growth because it allows tumor cells to
obtain enough oxygen and nutrients for their survival; anti-
angiogenesis has played a major role in cancer research.
Recently, many antiangiogenic agents have been developed,
and some of these are in clinical use. However, combination
treatment of antiangiogenic agents and radiotherapy in clin-
ics is still in its early stages. No antiangiogenic agents have
yet been approved for clinical treatment in combination with
radiation therapy.
3.3.1. Angiostatin and Endostatin. Angiostatin, which is
a proteolytic fragment of plasminogen and an intrinsic
angiogenic inhibitor, was reported to have the potential
to enhance the antitumor effects of radiation [45]. Itasaka
et al. showed that endostatin, an endogenous angiogenesis
inhibitor, enhanced the tumor response to radiation and
blocked tumor revascularization aer radiation treatment
[49]. Another group reported that recombinant human endo-
statin radiosensitized xenograed human nasopharyngeal
carcinoma in mice [50]. However, these inhibitors have
not yet been clinically used in combination with radiation
therapy.
3.3.2. Anti-VEGF Antibody. VEGF is one of the promis-
ing targets for anticancer therapy. Neutralization of VEGF
inhibited the growth of primary tumors and metastases [53].
Blocking VEGF with a neutralizing antibody enhanced the
antitumor effects of radiation in preclinical studies [36].
Another group reported that an anti-VEGF monoclonal
antibody in combination with radiation led to tumor growth
delay in mouse xenogra models [54].
Bevacizumab is a humanizedmonoclonal antibodywhich
neutralizes the VEGF ligand. Bevacizumab in combination
with cytotoxic chemotherapy showed a signi�cant improve-
ment in survival in patients with advanced colorectal or lung
cancer [114, 115]. Currently bevacizumab is approved for
use in combination with cytotoxic chemotherapy in those
diseases. e combination therapy of bevacizumab with
radiation is also a promising strategy to improve the antitu-
mor effects. A clinical trial with a combination of radiation
therapy plus 5-FUwith bevacizumab followed by surgery was
done and led to encouraging results in patients with locally
advanced rectal cancer [116]. e combination of radiation
therapy with bevacizumab resulted in promising responses
in locally advanced inoperable colorectal cancer [117]. e
addition of bevacizumab to neoadjuvant chemoradiotherapy
using capecitabine resulted in encouraging pathologic com-
plete response with tolerable toxicity for locally advanced
rectal cancer [118]. Further clinical studies are required
to assess the role of combination therapy of bevacizumab
with radiation or chemoradiation in patients with rectal
cancers.
A phase II study was conducted to evaluate the use of
bevacizumab in combination with concurrent capecitabine
and radiation therapy followed by maintenance gemcitabine
and bevacizumab for patients with locally advanced pan-
creatic cancer. e median overall survival and the median
progression-free survival time were similar to the results
obtained in prior RTOG trials with conventional chemora-
diotherapy [119]. is result implies that the addition of
bevacizumab does not improve the efficacy of conventional
chemoradiotherapy in patients with locally advanced pancre-
atic cancer. Currently, several clinical trials using combina-
tion therapy of bevacizumab with radiation or chemoradi-
ation are ongoing in patients with other malignant tumors
such as glioblastoma or head and neck cancers [120, 121].
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3.3.3. Anti-VEGFR Agents. DC101 is a VEGFR2 antibody,
and it was reported to reduce the radiation dose necessary
to control tumor models [43]. DC101 in combination with
radiation showed a synergistic effect when irradiation was
performed several days aer the administration of DC101
[55]. Many groups have shown that the VEGF receptor
tyrosine kinase inhibitors enhance the radiation response
in preclinical studies. Radiation treatment with the VEGF
receptor tyrosine kinase inhibitor, PTK787/ZK222584 (vata-
lanib), delayed tumor growth in colon tumor xenogras
[57]. e combination of another VEGFR tyrosine kinase
inhibitor, ZD6474 (vandetanib), and radiation, led to sig-
ni�cant enhancement of antiangiogenic, antivascular, and
antitumor effects in an orthotopic model of lung cancer [59].
AZD2171 (cediranib) is a potent VEGFR tyrosine kinase
inhibitor, and it has been reported to radiosensitize tumor
xenografs [60, 61]. Several clinical trials using these agents
with radiation therapy are now being performed [122].
3.3.4. Inhibitors of VEGFR2, PDGFR, c-kit and Fetal Liver
Tyrosine Kinase 3. Sunitinib (SU11248) is a multityrosine
kinase inhibitor of VEGFR2, PDGFR, c-kit, and fetal liver
tyrosine kinase 3, and it was reported to radiosensitize tumor
cells in preclinical studies [65, 66]. Now, several clinical trials
using sunitinib in combination with radiation therapy are
ongoing [123, 124].
3.3.5. Other Agents. (1) alidomide. alidomide is an
orally administered drug which inhibits angiogenesis [69]
and has been recognized to have several antitumor and
antimetastatic mechanisms. Radiation erapy Oncology
Group (RTOG) conducted a phase III study to compare
whole-brain radiation therapy (WBRT) with WBRT com-
bined with thalidomide for patients with brain metastases
(RTOG0118), but thalidomide with radiation therapy pro-
vided no survival bene�t [125].
(2) Inhibitors of the EGFR/RAS/PI3 K/Akt/mTOR Pathway.
Preclinical studies showed that the anti-EGFR monoclonal
antibody C225 (cetuximab) enhanced the radiosensitivity
of tumor cells [126]. A phase III trial using a combination
of cetuximab and radiation therapy signi�cantly improved
overall survival at 5 years compared with radiation therapy
alone in the treatment of locally advanced head and neck
squamous cell carcinoma [127]. Many other inhibitors of
these pathways have been shown to enhance tumor radiosen-
sitivity at clinically relevant doses in preclinical experiments
[78, 128–132].
Qayum and colleagues showed that inhibition of EGFR-
Ras-PI3K-Akt signaling at multiple points in this pathway
led to vascular normalization accompanied by improved
tumor oxygenation and perfusion. Cerniglia et al. showed
that erlotinib (an EGFR inhibitor) treatment of mice bear-
ing xenogras led to reduced VEGF expression, enhanced
vascular functioning in the tumors, increased blood �ow,
and improved oxygenation, resulting in enhancement of
radiosensitivity. Moreover, Fokas and colleagues reported
that a dual inhibitor of phosphoinositide-3-kinase (PI3K)
and mTOR improved vascular structure over a prolonged
period. ese studies have shown that inhibition of signaling
through EGFR, RAS, PI3-Kinase, AKT, and mTOR results in
enhanced vascular function, which may be one of the mech-
anisms by which inhibitors of these pathways radiosensitize
tumor cells.
4. Conclusion
e tumor microenvironment has been the main focus and
the therapeutic target in the �eld of radiation biology and
oncology in terms of tumor hypoxia. Understanding of the
biological response to hypoxia through HIF-1 revealed many
molecules and complicated pathways related to survival of
cells and progression of malignancy. In addition to direct
approaches to hypoxia, targeting molecular pathways related
to HIF-1 pathways is promising to improve the efficacy of
radiation therapy. Tumor angiogenesis is also a good target
for cancer therapy. Either direct or indirect inhibition of
angiogenesis can enhance the effects of radiation therapy.
Since radiation therapy itself has a great impact on host
cells like vascular endothelial cells, it has become clear that
changes in the tumor microenvironment during therapy and
the optimal timing of the combination is a key to achieving
maximal therapeutic effects in the combination therapy of
radiation and microenvironment targeting. However, we still
have further challenges to incorporate targeting therapy for
the microenvironment to improve the effects of radiation
therapy in clinics, and this will lead to greater knowledge
about how radiation therapy works in cancer therapy and
thus further improvements in radiation therapy.
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